Ultragenyx Pharmaceutical (RARE) reported a Q4 net loss Thursday of $1.39 per diluted share, narrowing from the loss of $1.52 a year earlier.
Analysts polled by FactSet expected a per-share loss of $1.31.
Revenue in the three months ended Dec. 31 rose to $164.9 million from $127.4 million a year earlier.
Analysts surveyed by FactSet expected $151.9 million.
The company expects 2025 revenue of $640 million to $670 million.
Analysts polled by FactSet expect $642.9 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。